Studies from Stanford University yield new information about follicular lymphoma
2009 JUL 8 - (NewsRx.com) -- "Polymorphisms of activating FcRIIIa (CD16) and FcRIIa (CD32a) have been found to predict rituximab response, probably because of the relative efficiency of different FcR variants in performing antibody-dependent cellular cytotoxicity. The inhibitory FcRIIb (CD32b) has an opposing effect on effector cells," scientists in the United States report. "Here, we examined whether an FcRIIb 232 isoleucine (I)/threonine (T) polymorphism predicts rituximab response in 101 patients with follicular lymphoma. Eighty-four patients were 232 I/I, 15 were 232 I/T and two were 232 T/T. The response rate was similar among the three groups. The 2-year progression free survival (PFS) and median time to progression (TTP) were not different between I/I and I/T groups. The TTP was not determined in T/T group because of small number of patients. The FcRIIIa 158 V/V and FcRIIa 131 H/H genotypes continued to emerge as independent predictors for higher response rate and longer TTP," wrote W.K. Weng and colleagues, Stanford University. The researchers concluded: "This study is the first to determine whether inhibitory FcRIIb play a role in rituximab's anti-tumor effect in humans.." Weng and colleagues published their study in Leukemia & Lymphoma (Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leukemia & Lymphoma, 2009;50(5):723-727). For additional information, contact W.K. Weng, Stanford University, School Medical, Division Blood & Marrow Transplantation, Dept. of Medical, 300 Pasteur Dr., Room H3249, Stanford, CA 94305, USA. The publisher's contact information for the journal Leukemia & Lymphoma is: Taylor & Francis Ltd., 4 Park Square, Milton Park, Abingdon OX14 4RN, Oxon, England. Keywords: United States, Stanford, Biological Therapy, Biotechnology, Follicular Lymphoma, Genetics, Hematology, Hodgkin Disease, Immunotherapy, Leukemia, Medical Device, Monoclonal Antibodies, Oncology, Treatment, Stanford University. This article was prepared by Immunotherapy Weekly editors from staff and other reports. Copyright 2009, Immunotherapy Weekly via NewsRx.com.
|
